quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·143d
NEWSRelease
NanoViricides Inc. logo

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NNVC· NanoViricides Inc.
Health Care
Original source

Companies

  • NNVC
    NanoViricides Inc.
    Health Care

Recent analyst ratings

  • Dec 16UpdateAlliance Global Partners-

Related

  • NEWS2d
    Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
  • NEWS16d
    Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
  • NEWS22d
    Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
  • NEWS43d
    NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
  • SEC65d
    SEC Form 10-Q filed by NanoViricides Inc.
  • NEWS70d
    MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
  • NEWS72d
    Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
  • NEWS80d
    NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022